4,4'-(ethane-1,1-diyl)bis(fluorobenzene) | 395-24-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-(ethane-1,1-diyl)bis(fluorobenzene)
• 英文别名: 1,1a(2)-Ethylidenebis[4-fluorobenzene]；1-fluoro-4-[1-(4-fluorophenyl)ethyl]benzene
• CAS: 395-24-4
• 化学式: C₁₄H₁₂F₂
• 分子量: 218.246
• InChiKey: PQIFKFHXSASQOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4'-(ethane-1,1-diyl)bis(fluorobenzene) 在 乙醇 、 trisaminocyclopropenium 、 水 、 N,N,N,N-tetraethylammonium tetrafluoroborate 、 三氟乙酸 、 potassium hydroxide 作用下， 以 乙二醇 为溶剂， 生成 1,1-双(4-氟苯基)-1,2-乙二胺
  参考文献：
  名称：

  邻位CH键的电光催化加氨基

  摘要：

  未活化的碳氢键（C–H）转换为碳氮键（C–N）是非常有价值的转化。现有的策略通常仅在单个CH位置完成此类反应，因为第一次衍生化会降低周围CH键的反应性。在这里，我们表明烷基化的芳烃可以通过邻位的CH氨化反应，通过电光催化策略使用乙腈作为溶剂和氮源，形成1,2-二胺衍生物。该反应由三氨基环丙烯（TAC）离子催化，该离子经过阳极氧化以提供稳定的自由基指示，而阴极反应则将质子还原为分子氢。用白光紧凑型荧光灯照射TAC自由基指示剂（最大吸收波长为450至550纳米）会产生强烈氧化的光激发中间体。取决于所使用的电解质，可获得3，4-二氢咪唑或氮丙啶产物。

  DOI：

  10.1126/science.abf2798
• 作为产物：
  描述：

  1,1-bis-(4-fluoro-phenyl)-ethanol 在 Ca zeolite 、 对甲苯磺酸 作用下， 以 正己烷 、 苯 为溶剂， 反应 3.0h， 生成 4,4'-(ethane-1,1-diyl)bis(fluorobenzene)
  参考文献：
  名称：

  Activation Conditions Play a Key Role in the Activity of Zeolite CaY:  NMR and Product Studies of Brønsted Acidity

  摘要：

  CaY, activated under different conditions, was characterized with H-1, (31)p, and H-1/27AI double resonance MAS NMR. The H-1 MAS NMR spectra of CaY, calcined in an oven at 500 degrees C, shows resonances from H2O (bound to Ca2+ and the zeolite framework), CaOH+, aluminum hydroxides, silanols, and Bronsted acid sites. No evidence for Lewis acidity is observed on adsorption of trimethylphosphine, and an estimate of approximate to 16 Bronsted acid sites per unit cell is obtained for this sample. CaY activated in an oven at higher temperatures contains less water, but all the other species are still present. In contrast, CaY activated by slow ramping of the temperature under vacuum to 500 or 600 degrees C shows a; much lower concentration of Bronsted acid sites (<1/unit cell). Again, no evidence for Lewis acidity was observed. These NMR results have been utilized to understand the very different product distributions that are observed for reactions of 1,1- and 1,2-diarylethylenes in zeolite CaY activated in an oven (in air) and under vacuum. Samples with high concentrations of Bronsted acid sites react stoichiometrically with these sites, yielding diarylalkanes. At low concentrations, the Bronsted acid sites can act catalytically resulting in isomerization reactions.

  DOI：

  10.1021/jp980385w

文献信息

• [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2015078374A1

  公开（公告）日：2015-06-04

  The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  这项发明提供了具有一般式I的化合物及其药用盐，其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• HIV PROTEASE INHIBITORS
  申请人：MCCAULEY John A.

  公开号：US20170217986A1

  公开（公告）日：2017-08-03

  The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z 1 , Z 2 , V 1 , V 2 , V 3 , R 6 , R 6A , and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  本发明涉及Formula (I)的2,6-吗啉衍生物及其药用盐，其中Z1、Z2、V1、V2、V3、R6、R6A和X在此被定义。该发明还涉及使用该发明的2,6-吗啉衍生物来抑制HV蛋白酶、抑制HV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病的发作或进展的方法。这些化合物及其盐可作为药物组合物中的成分使用，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• [EN] SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS<br/>[FR] COMPOSÉS DE QUINOLINONYLE PIPÉRAZINE SUBSTITUÉS UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021133748A1

  公开（公告）日：2021-07-01

  Disclosed are compounds of Formula (I) or a salt thereof, wherein: R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα ) and diacylglycerol kinase zeta (DGKξ ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)或其盐的化合物，其中：R1、R2、R3、R4、R5、R6和m在此处被定义。还揭示了使用这些化合物来抑制二酰甘油激酶α(DGKα)和二酰甘油激酶ξ(DGKξ)中一种或两种活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增殖性疾病，如癌症方面是有用的。
• Cyclohexa-1,3-diene-based dihydrogen and hydrosilane surrogates in B(C₆F₅)₃-catalysed transfer processes
  作者：Weiming Yuan、Patrizio Orecchia、Martin Oestreich

  DOI：10.1039/c7cc06195a

  日期：——

  Transition-metal-free transfer hydrogenation and transfer hydrosilylation of alkenes are achieved with cyclohexa-1,3-diene-based surrogates.

  无过渡金属的烯烃转移氢化和转移氢硅烷化可以通过基于环己烯-1,3-二烯的替代物实现。
• [EN] COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS<br/>[FR] COMBINAISONS D'INHIBITEURS DE DGK ET D'ANTAGONISTES DE POINTS DE CONTRÔLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021127554A1

  公开（公告）日：2021-06-24

  Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD1/PD-L1 axis and/or an antagonist of CTLA4.

  提供了二酰甘油激酶（DGK）的抑制剂以及用于治疗需要刺激免疫系统的疾病的方法，如癌症和感染性疾病，包括通过联合给予DGK抑制剂和PD1/PD-L1轴的拮抗剂和/或CTLA4的拮抗剂来治疗。